ReproCELL Incorporated

DB:6RC Stock Report

Market Cap: €57.6m

ReproCELL Past Earnings Performance

Past criteria checks 0/6

ReproCELL has been growing earnings at an average annual rate of 35.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 19.6% per year.

Key information

35.5%

Earnings growth rate

38.8%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate19.6%
Return on equity-2.2%
Net Margin-7.5%
Next Earnings Update13 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How ReproCELL makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:6RC Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,599-1951,177453
30 Jun 242,489-1781,187418
31 Mar 242,426-311,131384
31 Dec 232,506-2181,088429
30 Sep 232,524-3131,057459
30 Jun 232,843-2751,010481
31 Mar 232,953-305984501
31 Dec 222,969-263936468
30 Sep 222,821-306927466
30 Jun 222,518-411893466
31 Mar 222,234-575898535
31 Dec 211,825-505898571
30 Sep 211,661-648875642
30 Jun 211,500-726884713
31 Mar 211,286-812843662
31 Dec 201,257-1,011883626
30 Sep 201,249-945859558
30 Jun 201,111-995859482
31 Mar 201,199-1,016889454
31 Dec 191,173-834886388
30 Sep 191,114-809943317
30 Jun 191,090-750964282
31 Mar 191,088-601971273
31 Dec 181,046-1,950805277
30 Sep 181,018-1,965846264
30 Jun 18969-2,052908233
31 Mar 18926-2,172982191
31 Dec 171,083-1,0191,122203
30 Sep 171,187-7591,071237
30 Jun 171,202-7651,031256
31 Mar 171,257-9111,011276
31 Dec 161,136-1,838882277
30 Sep 161,043-2,150958274
30 Jun 161,069-2,199984282
31 Mar 161,066-1,961979289
31 Dec 151,023-7911,218337
30 Sep 15917-7201,111340
30 Jun 15743-518947316
31 Mar 15567-451736280
31 Dec 14473-359487186
30 Sep 14463-187345147
30 Jun 14462-140268133
31 Mar 14460-133229120

Quality Earnings: 6RC is currently unprofitable.

Growing Profit Margin: 6RC is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 6RC is unprofitable, but has reduced losses over the past 5 years at a rate of 35.5% per year.

Accelerating Growth: Unable to compare 6RC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6RC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).

Return on Equity

High ROE: 6RC has a negative Return on Equity (-2.23%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:42
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ReproCELL Incorporated is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Akinori UedaGoldman Sachs